Antiphospholipid Syndrome (APS) is an autoimmune disease characterized by recurrent thromboses and fetal losses with the presence of antiphospholipid antibodies. The main treatment to prevent recurrent thrombotic events is oral anticoagulation with vitamin K antagonist (VKA), which requires frequent monitoring and dosage adjustments. Outpatient anticoagulation monitoring has its limitations, such as patients spending long hours between the testing procedure and waiting for the results to be adjusted. To optimize this adjustment and to improve APS patients-doctors relationship, we developed a website to help monitor APS patients, called Antiphospholipid Syndrome On Cloud or APSOnCloud. To test it, since March 2014 to March 2016, we registered 20 patients with APS that have inserted 132 international normalized ratio (INR) values. Sixty two percent were out of range and it took on average 7 hours for the doctor in charge to adjust these values. The mean time in therapeutic range was 58.1%. Our preliminary experience in monitoring VKA oral anticoagulation on APSOnCloud suggests that patients with APS might benefit from this web-based monitoring.
MiyakisSLockshinMDAtsumiT. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost2006; 4: 295–306.
2.
Cervera R, Serrano R, Pons-Estel GR, et al. Morbidity and mortality in the antiphospholipid syndrome during a 10-year period: a multicentre prospective study of 1000 patients. Ann Rheum Dis 2015; 74: 1011–1018.
3.
LeeACrowtherM. Practical issues with vitamin k antagonists: elevated INRs, low time-in-therapeutic range, and warfarin failure. J Thromb Thrombolysis2011; 31: 249–258.
4.
NutescuEChuatrisornIHellenbartE. Drug and dietary interactions of warfarin and novel oral anticoagulants: an update. J Thromb Thrombolysis2011; 31: 326–343.
5.
Fuster V, Rydén LE, Cannon DS, et al. 2011 ACCF/AHA/HRS focused updates incorporated into the ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation 2011; 123: e268–e367.
6.
Ruiz-IrastorzaGHuntBJKhamashtaMA. A systematic review of secondary thromboprophylaxis in patients with antiphospholipid antibodies. Arthritis Rheum2007; 57: 1487–1495.
7.
BloomfieldHEKrauseAGreerN. Meta-analysis: effect of patient self-testing and self-management of long-term anticoagulation on major clinical outcomes. Ann Intern Med2011; 154: 472–482.
8.
RosendaalFRCannegieterSCvan der MeerFJ. A method to determine the optimal intensity of oral anticoagulant therapy. Thromb Haemost1993; 69: 236–239.
9.
FerreiraFAntunesRNevesRC. INR telemonitoring: Efficacy and safety of a telemonitoring program in 453 patients. Acta Med Port2012; 25: 297–300.
10.
Grzymala-LubanskiLSjälanderSRenlundH. Computer aided warfarin dosing in the Swedish national quality registry AuriculA – Algorithmic suggestions are performing better than manually changed doses. Thromb Res2013; 131: 130–134.
11.
RyanFByrneSO'SheaS. Randomized controlled trial of supervised patient self-testing of warfarin therapy using an internet-based expert system. J Thromb Haemost2009; 7: 1284–1290.
12.
CafollaAMelizziRBaldacciE. “Zeus” a new oral anticoagulant therapy dosing algorithm: A cohort study. Thromb Res2011; 128: 325–330.
ErkanDLockshinMD. APS ACTION – AntiPhospholipid Syndrome Alliance For Clinical Trials and InternatiOnal Networking. Lupus2012; 21: 695–698.
15.
LevyRSignorelliF. Patient−health care provider relationship: How can it impact on APS (Hughes' syndrome) adherence to treatment?Lupus2014; 23: 1265–1268.
16.
PastoriDParrottoSVicarioT. Antiphospholipid syndrome and anticoagulation quality: A clinical challenge. Atherosclerosis2016; 244: 48–50.
17.
DouketisJDSinghD. Self-monitoring and self-dosing of oral anticoagulation improves survival. Evid Based Cardiovasc Med2006; 10: 124–126.
18.
ConnockMStevensCFry-SmithA. Clinical effectiveness and cost-effectiveness of different models of managing long-term oral anticoagulation therapy: A systematic review and economic modelling. Health Technol Assess2007; 11: iii–iv.
19.
WellsPSBrownAJaffeyJ. Safety and effectiveness of point-of-care monitoring devices in patients on oral anticoagulant therapy: A meta-analysis. Open Medicine2007; 1: e131–146.
20.
ChristensenTDJohnsenSPHjortdalVE. Self-management of oral anticoagulant therapy: A systematic review and meta-analysis. Int J Cardiol2007; 118: 54–61.
21.
Health Quality Ontario. Point-of-Care International Normalized Ratio (INR) Monitoring Devices for Patients on Long-term Oral Anticoagulation Therapy. Ont Health Technol Assess Ser2009; 9: 1–114.
22.
Garcia-AlaminoJMWardAMAlonso-CoelloP. Self-monitoring and self-management of oral anticoagulation. Cochrane Database Syst Rev2010. CD003839.
23.
BloomfieldHEKrauseAGreerN. Meta-analysis: Effect of patient self-testing and self-management of long-term anticoagulation on major clinical outcomes. Ann Intern Med2011; 154: 472–482.
24.
HeneghanCWardAPereraR. Self-monitoring of oral anticoagulation: Systematic review and meta-analysis of individual patient data. Lancet2012; 379: 322–334.
25.
XuZWangZOuJ. Two monitoring patients methods of oral anticoagulant therapy in patients with mechanical heart valve prothesis: A meta-analysis. J Thromb Thrombolysis2012; 33: 38–47.
26.
SiebenhoferAJeitlerKHorvathK. Self-management of oral anticoagulation. Dtsch Arztebl Int2014; 111: 83–91.
27.
Sharma P, Scotland G, Cruickshank M, et al. Is self-monitoring an effective option for people receiving long-term vitamin K antagonist therapy? A systematic review and economic evaluation. BMJ Open 2015; 5: e007758.
28.
WittkowskyAKSekretaCMNutescuEA. Barriers to patient self-testing of prothrombin time: National survey of anticoagulation practitioners. Pharmacotherapy2005; 25: 265–269.
29.
SignorelliFNogueiraFDominguesV. Thrombotic events in patients with antiphospholipid syndrome treated with rivaroxaban: A series of eight cases. Clin Rheumatol2016; 35: 801–805.
